Research Reference
AHK-Cu
Topical copper peptide — scalp and hair research (no validated dose)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
AHK-Cu is a copper-binding tripeptide (alanine-histidine-lysine complexed with copper) used topically rather than by injection. The research powder is reconstituted into a serum and applied to the scalp or skin, often alongside microneedling. This makes "dosing" a question of concentration and application frequency, not injected milligrams.
AHK-Cu has no established human dosing protocol. The most-cited study (Pyo et al., 2007) tested AHK-Cu on isolated human hair follicles and dermal papilla cells in culture — not as a topical product on people. The numbers below come from self-reported community formulations and the lesser sibling relationship to GHK-Cu, not from clinical dose-finding.
Side Effects & Safety
Topical copper peptides are generally well tolerated in cosmetic use, with the main documented concerns being local: irritation, redness, or, less commonly, allergic contact dermatitis. Copper itself is a comparatively weak skin sensitizer — a 2014 review (PMID 25098945) reported positive copper patch-test reactions in roughly 3.8% of tested subjects — so contact allergy is possible but uncommon. Microneedling, where used as a penetration aid, adds its own local risks (transient redness, pinpoint bleeding) independent of the peptide.
Formal safety data specific to topical AHK-Cu is limited, and theoretical concerns such as copper accumulation with heavy long-term use have not been characterized in human studies.
Research Basis
The picomolar-to-nanomolar concentrations in the Pyo 2007 study (PMID 17703734) describe what was effective on cells in a dish; they are not a topical formulation percentage and cannot be read across to one. The ~1–2 mg/mL serum figures circulating in community sources are DIY formulation conventions, often borrowed from how GHK-Cu cosmetic serums are mixed, rather than results of any AHK-Cu human study.
The cell-culture data establishes biological plausibility for hair-follicle effects; the topical concentrations are community formulation practice. Both are reported with the gap between them stated rather than glossed over. Anyone treating a serum percentage as a validated dose is reading more certainty into the literature than exists.